In a nutshell This phase 2 study will investigate the effectiveness of experimental medication tucatinib and trastuzumab (Herceptin) to treat brain metastases in HER2-positive breast cancer (BC). The main outcome will be overall survival (OS). This trial is recruiting in Alabama and Texas, the US. The details...
Read MoreCurrent stage-Stage IV Posts on Medivizor
Internal selective radiotherapy improves the outcomes of patients with colorectal cancer liver metastasis
In a nutshell This study investigated the effectiveness of selective internal radiation therapy (SIRT) in the treatment of colorectal cancer liver metastasis (CRC-LM). Researchers suggested that adding this therapy to the treatment improves the outcomes of the treatment. Some background The liver is a common site for colorectal cancer metastasis...
Read MoreSearching for patients with advanced triple-negative breast cancer to test a new combination treatment
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with or without atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may...
Read MoreSearching for patients with advanced non-small cell lung cancer to test a new combination therapy
In a nutshell This phase 1b/2 trial will investigate the safety of cabozantinib (Cabometyx) with atezolizumab (Tecentriq) in patients with advanced solid tumors. The main outcomes will be the maximum tolerated dose (MTD) and overall response rate (ORR). The details Advanced cancers have limited treatment options. Surgery may not be possible. In...
Read MoreSearching patients with triple-negative breast cancer to trial a new treatment combination
In a nutshell This phase 1b/2 trial will investigate the safety of treatment with rucaparib (Rubraca) in combination with other anti-cancer agents (ACAs) in patients with triple-negative breast cancer and other solid tumors. The main outcomes will be the number of treatment-related side effects and response to treatment. This trial is...
Read MoreSearching for patients to try a new therapy for advanced solid tumors.
In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...
Read MoreSearching for patients to try a new therapy for advanced solid tumors.
In a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...
Read MoreSearching for patients with advanced solid tumors to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with melanoma to test a new medication
In a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced melanoma. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details Melanoma or skin cancer is one of the most common cancers. The...
Read MoreSearching for patients with non-small cell lung cancer to test a new treatment
In a nutshell This phase 2 trial will investigate the effect of vopratelimab (JTX-2011) and ipilimumab (Yervoy) in non-small cell lung cancer (NSCLC). The main outcome will be the overall response (OR). This trial is recruiting at multiple locations in the US. The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreSearching for patients with unresponsive cancer to test a new treatment
In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers. The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...
Read More
